Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100 U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
Rosenstock J, Handelsman Y, Vidal J, Ampudia Blasco FJ, Giorgino F, Liu M, Perfetti R, Meier JJ. Rosenstock J, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Dec;20(12):2821-2829. doi: 10.1111/dom.13462. Epub 2018 Aug 13. Diabetes Obes Metab. 2018. PMID: 29974618 Free PMC article.
Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial.
Metzger M, Castañeda J, Reznik Y, Giorgino F, Conget I, Aronson R, de Portu S, Runzis S, Lee SW, Cohen O. Metzger M, et al. Among authors: giorgino f. Diabetes Obes Metab. 2017 Oct;19(10):1490-1494. doi: 10.1111/dom.12960. Epub 2017 Jul 25. Diabetes Obes Metab. 2017. PMID: 28374511 Clinical Trial.
Effect of once-weekly dulaglutide on glycated haemoglobin (HbA1c) and fasting blood glucose in patient subpopulations by gender, duration of diabetes and baseline HbA1c.
Gallwitz B, Dagogo-Jack S, Thieu V, Garcia-Perez LE, Pavo I, Yu M, Robertson KE, Zhang N, Giorgino F. Gallwitz B, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Feb;20(2):409-418. doi: 10.1111/dom.13086. Epub 2017 Oct 5. Diabetes Obes Metab. 2018. PMID: 28817231 Free PMC article. Clinical Trial.
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study.
Fioretto P, Del Prato S, Buse JB, Goldenberg R, Giorgino F, Reyner D, Langkilde AM, Sjöström CD, Sartipy P; DERIVE Study Investigators. Fioretto P, et al. Among authors: giorgino f. Diabetes Obes Metab. 2018 Nov;20(11):2532-2540. doi: 10.1111/dom.13413. Epub 2018 Jul 10. Diabetes Obes Metab. 2018. PMID: 29888547 Free PMC article. Clinical Trial.
Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes.
Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Handelsman Y, et al. Among authors: giorgino f. J Diabetes Complications. 2019 Mar;33(3):236-242. doi: 10.1016/j.jdiacomp.2018.11.009. Epub 2018 Nov 30. J Diabetes Complications. 2019. PMID: 30600136 Free article. Clinical Trial.
384 results